A novel cytokine, U83A, is described, as are variant forms of the cytokine, having a wide range of agonistic and antagonistic activity against chemokine receptors. Uses of the chemokine in treatment of a range of diseases, including cancers and HIV/AIDS, are described.

Disclosed is a composition comprising at least one non-infectious virus particle for preventing and/or treating a viral infection in a marine mollusc.

This disclosure provides recombinant polycistronic nucleic acid molecules that contain at at least four nucleotide sequences that encode a protein of interest, particularly proteins that form complexes in vivo, each operably linked to a separate subgenomic promoter. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development.

The present invention relates to a vaccine composition comprising an effective amount of a replication-competent controlled recombinant virus. Further encompassed are uses in immunization and methods of immunization employing compositions comprising a replication-competent controlled recombinant virus of the invention.

The present invention provides vaccine or immunogenic compositions comprising novel antigens derived from the equine strain of influenza H3N8. These proteins and specific immunogenic domains are effective as primary universal influenza antigens. The disclosed vaccines or immunogenic compositions are highly effective in inducing HA specific antibodies reactive to different influenza viruses, mucosal and systemic immune responses, and cross-protection regardless of influenza virus subtypes. In some embodiments, the vaccine is cross-protective against two or more (e.g., 2, 3, 4, 5, or 6) subtypes of influenza with or without the use of an adjuvant.

The invention relates to a bonding and forming device for an inner box of a paper box and surface paper. The bonding and forming device comprises a stand, a lifting platform, a paper box inner support member, a flanging pressing plate, an ejector pin, a left hairbrush, a right hairbrush, a first pushing part, a front hairbrush, a rear hairbrush and a second pushing part and also comprises a driving device, a first control device a second control device, a third control device, a fourth control device and a fifth control device, wherein the driving device is used for driving the ejector pin to rise or fall; the first control device is used for controlling the paper box inner support member to rise or fall; the second control device is used for controlling the left hairbrush and the right hairbrush to stretch; the third control device is used for controlling the first pushing part to stretch; the fourth control device is used for controlling the front hairbrush and the rear hairbrush to stretch; the fifth control device is used for controlling the second pushing part to stretch; an inhibiting device is arranged between the first control device and the driving device; and the paper box inner support member and the flanging pressing plate are respectively provided with a through hole for the ejector pin to pass through. By adopting the technical scheme, according to the bonding and forming device for the inner box of the paper box and the surface paper, provided by the invention, the inner box and other surfaces of the surface paper can be automatically bonded to be formed after a bottom plate of the inner box and the bottom surface of the surface paper are bonded. The degree of automation is high and the production efficiency is high.

The present disclosure relates to liquid and dried compositions comprising a live, attenuated or genetically modified herpesvirus and methods of preparing such compositions, in one aspect, the composition comprises at least two or more pharmaceutically acceptable exctpients, at least one of which is histidine and at least one of which is a sugar or sugar alcohol. The compositions retain a sufficiently high infectious titre following storage or large-scale manufacturing steps, such as lyophilization.

The present invention relates to the field of (vector) vaccines, and especially to novel promoter sequences, expression cassettes and vectors, which are suitable to express genes of interest, especially antigen encoding sequences. The viral vectors of the present invention are useful for producing an immunogenic composition or vaccine.

Provided herein are improved vaccines for HSV-2.

The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. The present disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa.